Physician profile
David A Patrick
NPI 1457633968
$4,005.55
in general payments reported to CMS, 2019-2025
26 companies · $1,033 in 2025
The $1,033 reported for 2025 was more than what 85% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $436 · 2022: $802 · 2023: $834 · 2024: $901 · 2025: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $716.06 | 2021-2025 | |
| Abbott Laboratories | $659.02 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $474.76 | 2021-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $452.79 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $385.01 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $336.33 | 2021-2025 | Amvuttra, Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.79 | 2022-2025 | Jardiance |
| Cvrx, INC. | $137.16 | 2021-2025 | Barostim Neo System |
| Bayer Healthcare Pharmaceuticals INC. | $80.85 | 2022-2025 | |
| Novo Nordisk INC | $72.61 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $67.54 | 2025 | Livtencity |
| Astrazeneca Pharmaceuticals Lp | $60.01 | 2024 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $53.05 | 2021-2024 | Camzyos |
| Kiniksa Pharmaceuticals, Ltd. | $32.21 | 2022-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $31.33 | 2023-2024 | Inpefa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $26.79 | 2023 | Prevena |
| Impulse Dynamics (USA) INC. | $25.93 | 2024 | Optimizer |
| Atricure, INC. | $22.37 | 2025 | Synergy Ablation System |
| Actelion Pharmaceuticals US, INC. | $21.90 | 2024 | Uptravi, Opsumit |
| Kestra Medical Technology Services, INC. | $18.84 | 2023 | Assure Wcd |
| Daiichi Sankyo INC. | $18.25 | 2023 | Injectafer |
| Argon Medical Devices, INC. | $16.36 | 2025 | Clot Management |
| Nuwellis, INC. | $15.81 | 2022 | |
| Heartflow, INC. | $15.48 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $14.62 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $13.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.